Navigation Links
The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
Date:8/20/2013

BURLINGTON, Mass., Aug. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the dyslipidemia market will grow to just over $31 billion in 2022, at an annual rate of 2 percent from 2012. The launch of antidyslipidemic agents from two novel drug classes–PCSK9 and CETP inhibitors–will be the primary drivers of market growth, off-setting the voracious genericization that has and will continue to impact the market through 2022.

The Pharmacor advisory service entitled Dyslipidemia finds that, despite continued generic erosion of Pfizer's Lipitor (atorvastatin) and the launch of generic versions of AstraZeneca's/Shionogi's Crestor and Merck's ezetimibe franchise—Zetia (ezetimibe), Vytorin (ezetimibe/simvastatin), Liptruzet (ezetimibe/atorvastatin)—statins will remain the sales-leading drug class through 2022.

"The failure of non-statin drugs to demonstrate a cardiovascular outcomes benefit above that of statin therapy in clinical trial has further cemented the first-line status of the statin class, and eroded physician willingness to address residual risk by normalizing non-LDL lipids," said Decision Resources Analyst Pam Narang, M.Sc., Ph.D. "Decision Resources expects the recent outcome of the HPS2-THRIVE study that investigated the effect of HDL-C raising with Merck's Tredaptive to spell the end for niacin-based drugs.  Yet we see continued physician optimism for CETP inhibitors, which also primarily target HDL-C. While this enthusiasm is driven by their additional LDL-C lowering ability, the pendulum appears to be swinging back to LDL-C as the most robust modifiable dyslipidemia target, according to experts we interviewed."

The report findings also reveal the result of the outcomes trial IMPROVE-IT for ezetimibe is the most highly anticipated near-term event in the dyslipidemia market. Positive data from this trial will have a significant effect on physician prescribing and provide further validation of the LDL-C hypothesis, which will impact emerging LDL-C lowering agents such as the PCSK9 inhibitors. These agents will initially target the most high-risk patients. Launching in a specific patient subpopulation with the intention of gaining a broader label is an established development strategy, and one previously employed for prescription omega-3 fatty acids, Amarin's Vascepa and AstraZeneca's Epanova.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
9. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
10. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Radiology has become the number one ... also spiraled to the number one ranking as a ... ever before as the most complete and reliable method ... lower back pain an MRI may confirm a suspected ... resulting in entirely different treatment protocols.  In these circumstances, ...
(Date:5/9/2017)... 2017  Semler Scientific, Inc. (OTCQB: SMLR), an ... improve the clinical effectiveness and efficiency of healthcare ... quarter ended March 31, 2017. ... to identify when preventive care options are appropriate, ... heart attacks or strokes occur," said Doug ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. ... add approximately 100,000 square feet to its Welch Allyn ... 2016 its commitment to bring more than 100 new ... where Welch Allyn has maintained a significant presence for ... accommodate these new positions, a large portion of which ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information resource ... the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders ... healthcare industry today. , Out of more than 500 submissions, 100 winners were ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population ... Best in KLAS category winner, has named Daniel P. Bullington as chief technology ... its technology platform and product offerings,” says Justin Neece, president. “Daniel is an ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery ... Kevin Sadati, is pleased to announce a new treatment option called Vivace Microneedling. ... their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... equipment provider in the modern ART laboratory, to provide hands-on training utilizing cutting-edge ... Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide ...
(Date:5/23/2017)... Boston, MA (PRWEB) , ... May 23, 2017 , ... ... workshop on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and ... Premier Connected Home Event hosted by Parks Associates, a market research and consulting ...
Breaking Medicine News(10 mins):